---
title: "China's Finance Ministry Injects Capital Into ICBC as Offshore Brokers Stabilize"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298311040.md"
description: "State-led recapitalizations are reshaping the financial landscape, with ICBC receiving fresh funding in September 2026. Meanwhile, energy and consumer companies are navigating shifting industry cycles with mixed results."
datetime: "2026-09-08T11:32:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298311040.md)
  - [en](https://longbridge.com/en/news/298311040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298311040.md)
generator: "portal-rs"
---

# China's Finance Ministry Injects Capital Into ICBC as Offshore Brokers Stabilize

In September 2026, the Ministry of Finance stepped in to recapitalize eight state-owned financial institutions, a move that prominently included **工商银行 (3316.HK)**. This capital injection serves as a significant macro signal, providing a thicker capital buffer for the banking giant amidst broader economic adjustments. It also highlights the government's ongoing effort to fortify the core of its financial system.

The ripple effects of state backing and market normalization are visible elsewhere in the financial sector. Over at the offshore flagship platform **申万宏源 (0218.HK)**, the first half of 2026 saw a modest but symbolic net profit of HKD 60.58 million. Having turned a corner from its multi-year losses in 2025, the firm is now leveraging its parent company's central state-owned enterprise (CSOE) credit endorsement to stabilize its cross-border investment banking operations.

**Also in the market...**

-   **Management shakeup in solar:** Over in the photovoltaic space, **新特能源 (1799.HK)** is navigating an industry downturn. The company reported a narrowed net loss of RMB 212 million for the first half of 2026, coupled with a sudden leadership transition as General Manager Nan Xinjian departed in August, handing the reins to 38-year-old Wang Bin.
-   **Biotech milestones:** **李氏大药厂 (0950.HK)** continues its clinical push. In July 2026, the company's IND application for its proprietary ADC drug ZK2401 was accepted by Chinese regulators, targeting a potential trial approval by September.
-   **Consumer resilience:** While the broader retail environment remains challenging, **波司登 (3998.HK)** has leaned into its core brand strength. The apparel maker continues to expand its outdoor clothing lineup to drive revenue momentum.
-   **Battery upgrades:** **超威动力 (0951.HK)** is riding the demand for electric bicycle and energy storage solutions, having previously posted a robust total revenue of over RMB 54 billion in 2025.
-   **Under the radar:** Updates have been sparse for food and beverage operator **宾仕国际 (2051.HK)**, which filed its annual report in July 2026, as well as Cayman-incorporated **高门集团 (8106.HK)**. Meanwhile, both **先施 (1302.HK)** and **奇点能源 (1328.HK)** have kept a low profile with no major recent business developments disclosed.

### Related Stocks

- [03316.HK](https://longbridge.com/en/quote/03316.HK.md)
- [01799.HK](https://longbridge.com/en/quote/01799.HK.md)
- [03998.HK](https://longbridge.com/en/quote/03998.HK.md)
- [02051.HK](https://longbridge.com/en/quote/02051.HK.md)
- [08106.HK](https://longbridge.com/en/quote/08106.HK.md)
- [01302.HK](https://longbridge.com/en/quote/01302.HK.md)
- [01328.HK](https://longbridge.com/en/quote/01328.HK.md)

## Related News & Research

- [Zylox-Tonbridge to Invest HK$889.0M in LifeTech and Pursue Potential Merger](https://longbridge.com/en/news/304676052.md)
- [Zylox-Tonbridge, GL Capital Agree to Buy 16.7% Stake in LifeTech for HKD 1.48 Billion](https://longbridge.com/en/news/304675428.md)
- [CItech Announces Extraordinary Shareholders' Meeting](https://longbridge.com/en/news/304952696.md)
- [LifeTech Scientific Wins EU CE Certification for Coronary Scaffold System](https://longbridge.com/en/news/303675485.md)
- [Xinte Energy Raises Cap and Renews Key Connected Framework Deals With TBEA](https://longbridge.com/en/news/301997737.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**